...It would be surprising if pharmaceutical companies were not already engaged in developing drugs that specifically inhibit NKCC1. The first to gain official approval for the treatment of autism would be the real breakthrough. In the meantime, there is...
...Stunningly, a highly significant treatment effect emerged 6 months after treatment had ended. Receptive language skills of the group treated with donepezil plus choline had continued to improve over the ‘washout’ period, whereas those of the placebo...
...Anti-inflammatory drugs are targeted on the pathophysiology of ASD not on behavioral symptoms that occur as consequence. Many of those symptoms are assumed to be caused or at least exacerbated by neuroinflammation. Thus, when a drug successfully reduces...
...Developments that followed publication of this study were also unprecedented. Within a month, two major clinical trials with SFN involving individuals with ASD were commissioned by Governmental agencies. The first will be conducted at Rutgers University to...
...GWP has submitted a New Drug Application to FDA for approval of Epidiolex marketing and prescription for seizure control in Dravet and Lennox-Gastaut syndromes. FDA’s decision is expected this year. GWP is not stopping there. Phase III trials of...
...Guanfacine emerged as the most efficacious drug for managing hyperactivity in children with ASD. Yet almost as much attention was given for adjusting guanfacine doses as for methylphenidate to achieve a balance between efficacy and tolerability. Neither...
